LAUSR

OBJECTIVES To know the efficacy of different doses of dalbavancin in acute bacterial skin and skin structure infections (ABSSSIs) and versus other antibiotics. METHODS We performed a systematic review of dalbavancin efficacy for ABSSSIs. We selected 10 clinicals trials from MEDLINE and Cochrane databases for qualitative review. Of these, 5 trials compared one or two doses of dalbavancin versus other antibiotics such as vancomycin or linezolid. RESULTS Treatment outcomes with other antibiotics were not significantly different versus two doses of dalbavancin (OR 1.13; 95% CI 0.75-1.71; p = 0.55) or single dose dalbavancin (OR 0.98; 95% CI 0.19- 5.17; p = 0.98). One dose versus two doses of dalbavancin did not show significant differences in any of the treatment groups. In contrast, the global microbiological assessment results indicated a favorable outcome for two doses of dalbavancin compared to the single dose of dalbavancin (OR 2.96; 95% CI 1.19-7.39; p= 0.02) in both methicillin-resistant and methicillin-susceptible Staphylococcus aureus. CONCLUSION Either single dose or two dose dalbavancin treatment is as clinically effective as other antibiotics such as vancomycin and linezolid for the treatment of ABSSSIs.